To compare patient and Medicare savings from the use of optical coherence tomography (OCT) in guiding therapy for neovascular age-related macular degeneration (nvAMD) to the research investments madeCT by the National Institutes of Health (NIH) and the National Science Foundation (N in developing OSF).